---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-052289"
form_type: "8-K"
ticker: "TNGX"
cik: "0001819133"
company_name: "Tango Therapeutics, Inc."
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T22:34:58.935154+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tango Therapeutics appoints Adam Crystal as President, R&D; base salary $550k, equity grants

## Summary
- Adam Crystal, M.D., Ph.D., appointed President, Research & Development, effective Feb 27, 2023.
- Annual base salary of $550,000; one-time sign-on bonus of $275,000 (clawback if leaves before Feb 27, 2024).
- Equity grants: stock options for 487,500 shares and RSUs for 81,250 shares, with time-based vesting.
- Target annual cash incentive of 45% of base salary; severance includes 12 months salary and COBRA coverage.
- Crystal previously CMO at C4 Therapeutics and clinical program leader at Novartis.

## SEC filing metadata
- accession: 0001193125-23-052289
- form_type: 8-K
- ticker: TNGX
- cik: 0001819133
- company_name: Tango Therapeutics, Inc.
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819133/000119312523052289/0001193125-23-052289-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819133/000119312523052289/d297639d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-052289
- JSON: https://secwatch.observer/filing/0001193125-23-052289.json
- Plain text: https://secwatch.observer/filing/0001193125-23-052289.txt

## Key facts
- Executive change
  Adam Crystal was appointed as President, Research & Development at Tango Therapeutics, Inc..
  - Action: appointed
  - Role: President, Research & Development
  source text: On February 28, 2023, Tango Therapeutics, Inc. (“Tango” or the “Company”) announced that Adam Crystal, M.D., Ph.D., 46 years old, was appointed as the Company’s President, Research & Development, effective as of February 27, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819133/000119312523052289/0001193125-23-052289-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.